Level C· Early human research exploring benefitsCohort StudyEurope PMCOpen access

FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels

Queipo-Ortuño MI., Escoté X., Ceperuelo-Mallafré V., Garrido-Sanchez L., Miranda M., Clemente-Postigo M.

Cohort Study on Type 2 Diabetes, published in PLoS One (2012) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
PLoS One (2012)
Reported sample size
—
Source database
Europe PMC
PMID
23139800
PMCID
PMC3489666
DOI
10.1371/journal.pone.0048605
Citations
68

Abstract (original English)

Background FABP4 is predominantly expressed in adipose tissue, and its circulating levels are linked with obesity and a poor atherogenic profile. Objective In patients with a wide BMI range, we analyze FABP4 expression in adipose and hepatic tissues in the settings of obesity and insulin resistance. Associations between FABP4 expression in adipose tissue and the FABP4 plasma level as well as the main adipogenic and lipolytic genes expressed in adipose tissue were also analyzed. Methods The expression of several lipogenic, lipolytic, PPAR family and FABP family genes was analyzed by real time PCR. FABP4 protein expression in total adipose tissues and its fractions were determined by western blot. Results In obesity FABP4 expression was down-regulated (at both mRNA and protein levels), with its levels mainly predicted by ATGL and inversely by the HOMA-IR index. The BMI appeared as the only determinant of the FABP4 variation in both adipose tissue depots. FABP4 plasma levels showed a significant progressive increase according to BMI but no association was detected between FABP4 circulating levels and SAT or VAT FABP4 gene expression. The gene expression of FABP1, FABP4 and FABP5 in hepatic tissue was significantly higher in tissue from the obese IR patients compared to the non-IR group. Conclusion The inverse pattern in FABP4 expression between adipose and hepatic tissue observed

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
LiverAdipose TissueAdipocytesAnimalsMice, Inbred C57BLHumansMiceObesityDisease Models, AnimalRNA, Messenger

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research